Diabetes has become so commonplace in our societies that it is often accepted as an unavoidable, life-long condition – something to be managed rather than questioned. This deeply ingrained perspective, shaped by decades of experience, no longer reflects what is possible. Diabetes prevention and care are now on the cusp of a revolution. In the past few years, progress in understanding, treating and potentially curing diabetes has accelerated, with transformative innovations emerging across the spectrum of prevention and care. New technologies for self-management, advanced digital tools for healthcare professionals (HCPs) and artificial intelligence (AI) are reshaping how diabetes can be prevented, monitored and managed. At the same time, emerging evidence shows that remission of type 2 diabetes (T2D) is possible through a range of interventions. Understanding of the mechanisms linking diabetes to other chronic conditions is also improving, while new therapies have emerged that can delay type 1 diabetes (T1D) progression; and progress towards a functional cure for T1D is accelerating. Yet, despite this extraordinary scientific momentum, health outcomes resulting from real-world care for people living with diabetes (PwD) in Europe are still not reaching their full potential. Many people face delayed diagnosis or do not achieve their treatment targets. Access to the latest innovations remains uneven. The gap between what science now makes possible and what PwD actually experience in their routine care represents a missed opportunity to lower the risk of complications, improve quality of life and transform life with diabetes.

To address this gap, IDF Europe is striving to transform the lives of PwD, from early detection to cure, by advocating for innovative and equitable diabetes prevention and care. As part of this commitment, IDF Europe convened an Expert Day in December 2025, bringing together PwD, HCPs, researchers and policymakers to discuss the latest evidence in diabetes care and explore areas with transformative potential, including preventing and achieving remission of T2D, addressing diabetes as a driver of other chronic conditions and accelerating progress towards a cure for T1D.

Realising these opportunities will require coordinated policies, equitable access, sustained research investment and integrated, person-centred care to ensure that scientific breakthroughs translate into meaningful improvements in the lives of millions of Europeans living with diabetes.

Background: Initiation to Non-Invasive Ventilation (NIV) in amyotrophic lateral sclerosis
(ALS) can be implemented in an inpatient or outpatient setting.

Aims: We aimed to evaluate the efficacy of adaptation (the number of needed sessions) to home-based NIV compared to an outpatient one in ALS in terms of arterial carbon dioxide (PaCO2) improvement. NIV acceptance (mean use of >=5 h NIV per night for three consecutive nights during the adaptation trial), adherence (night-time NIV usage for >=150 h/month), quality of life (QoL), and caregiver burden were secondary outcomes.

Methods: A total of 66 ALS patients with indications for NIV were involved in this randomized
controlled trial (RCT): 34 underwent NIV initiation at home (home adaptation, HA) and 32 at multiple outpatient visits (outpatient adaptation, OA). Respiratory function tests were performed at baseline (the time of starting the NIV, T0) together with blood gas analysis, which was repeated at the end of adaptation (T1) and 2 (T2) and 6 (T3) months after T1. NIV adherence was measured at T2 and T3. Overnight cardiorespiratory polygraphy, Short Form Health Survey (SF-36), Caregiver Burden Inventory (CBI), Caregiver Burden Scale (CBS), and Zarit Burden Interview (ZBI) were performed at T0, T2, and T3. Results: Fifty-eight participants completed the study. No differences were found between groups in PaCO2 at T1 (p = 0.46), T2 (p = 0.50), and T3 (p = 0.34) in acceptance (p = 0.55) and adherence to NIV at T2 and T3 (p = 0.60 and p = 0.75, respectively). At T2, the patients’ QoL, assessed with SF-36, was significantly better in HA than in OA (p = 0.01), but this improvement was not maintained until T3 (p = 0.17).

Conclusions: In ALS, adaptation to NIV in the patient’s home is as effective as that performed in an outpatient setting regarding PaCO2, acceptance, and adherence, which emphasizes the need for further studies to understand the role of the environment concerning NIV adherence.

This study assessed the feasibility of implementing a hybrid hospital–provider company
(PC) clinical pathway for patients with chronic respiratory failure (CRF) through the adaptation and follow-up of non-invasive ventilation (NIV). Over a 3-month period, a PC physiotherapist case manager oversaw the adaptation process, making adjustments as necessary, using remote monitoring and home visits. Outcome measures, including the number of patients enrolled, serious adverse events, hospitalizations, survival rates, professional time allocation, NIV adherence, nocturnal apnea–hypopnea, and oxygen saturation, Δ arterial carbon dioxide pressure (PaCO2), dyspnea, Short Physical Performance Battery (SPPB), exercise tolerance, quality of life, physical activity, and patient satisfaction, were collected. The recruitment rate was 74% (nineteen patients). Commonly reported
adverse events included leakage, discomfort and sleep disturbance. Predominant interventions were four home visits (3; 4) and two NIV adjustments (1; 5). The overall program time commitment averaged 43.97 h per patient (being hospital 40 ± 11% and PC 60 ± 11%). Improvements in PaCO2, dyspnea, SPPB and exercise tolerance were observed by the third month. Adherence to NIV was high, with good or very good satisfaction with its use. This study demonstrates that a hybrid hospital–PC service for NIV adaptation and follow-up is not only feasible but also shows validity, reliability, and acceptability.

This study updates the prevalence estimates of sleep-disordered breathing (SDB) in the U.S., analysing data from the Wisconsin Sleep Cohort Study (1988–2011) and extrapolating it to the national population via NHANES data. Driven by the ongoing obesity epidemic, the researchers found that SDB rates have risen significantly over the last two decades, with relative increases ranging from 14% to 55% across various demographic subgroups. As of the 2007–2010 period, the prevalence of moderate-to-severe SDB is estimated at 10% for men aged 30–49, 17% for men aged 50–70, 3% for women aged 30–49, and 9% for women aged 50–70. These findings highlight a growing public health burden, as untreated SDB is linked to severe long-term sequelae such as hypertension, cardiovascular disease, and increased mortality.

Home mechanical ventilation (HMV) in the Netherlands is normally initiated in
hospital, but this is expensive and often a burden for the patient. In this randomised controlled study we investigated whether initiation of HMV at home in patients with chronic respiratory failure is non-inferior to an in hospital based setting.
Methods: Seventy-seven patients were included, of which 38 patients started HMV at home. All patients were diagnosed with chronic respiratory failure due to a neuromuscular or thoracic cage disease. Primary outcome was the arterial carbon dioxide (PaCO2) while quality of life and costs were secondary outcomes. Telemonitoring was used in the home group to provide therapeutic information, for example; transcutaneous carbon dioxide, oxygen saturation and ventilator information, to the caregivers. Follow-up was six months.
Results: PaCO2, improved by 0.72 kPa in the hospital group and by 0.91 in
the home group, both improvements being significant and the latter clearly not inferior.
There were also significant improvements in quality of life in both groups, again not being
inferior with home treatment.